Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
3.650
-0.490 (-11.84%)
Oct 13, 2026, 2:51 PM EDT - Market open
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.19 billion as of October 13, 2026. It is the 8,606th most valuable company in the world and the 2,048th biggest in the United States. Its market cap has decreased by 10.66% in one year.
Market Cap
1.19B
Enterprise Value
790.60M
1-Year Change
-10.66%
Global Rank
Country Rank
#2,048 United States
Category
ChartMarket Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.19B, an increase of 72.25%. That is a compound annual growth rate of 9.40%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 13, 2026 | 1.19B | -21.06% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ultragenyx Pharmaceutical | 1.52B |
| Syndax Pharmaceuticals | 1.52B |
| Immunocore Holdings | 1.51B |
| Maze Therapeutics | 1.51B |
| Kailera Therapeutics | 1.51B |
| Hemab Therapeutics Holdings | 1.48B |
| Rapport Therapeutics | 1.47B |
| GH Research | 1.45B |